Loan repayment & Update

TruSpine Technologies PLC

28 June 2023

 

28 June 2023

TruSpine Technologies plc

("TruSpine" or the "Company")

Loan repayment & Update

TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, announces that, further to the announcement on 25 April 2023, the Company has repaid the £100,000 loan and accrued interest under the Loan Agreement with Annabel Schild. The Funding Loan was repaid from existing cash resources following receipt of a HMRC R&D tax credit of approximately £200,000 ("Tax Credit").

Update on Working Capital

The Company has limited working capital resources and continues to carefully manage its cash position.

Capitalised terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Company's announcement of 25 April 2023.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation, and the Directors of the Company are responsible for the release of this announcement.

Enquiries:

TruSpine Technologies Plc	Tel: [phone]
Laurence Strauss, Chief Executive Officer
Cairn Financial Advisers LLP (AQSE Corporate Adviser)	Tel: [phone]
Liam Murray / Ludovico Lazzaretti
Oberon Capital (Joint Broker)	Tel: [phone]
Mike Seabrook / Chris Crawford
Peterhouse Capital Limited (Joint Broker & Financial Adviser)	Tel: [phone]
Lucy Williams / Duncan Vasey
Novus Communications (PR and IR)	Tel: [phone]
Alan Green / Jacqueline Briscoe	[e-mail]

 

END